Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants

Clinical trial NCT07068841 · COMPLETED

Trial details

NCT number: NCT07068841
Sponsor: Neurodawn Pharmaceutical Co., Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Pharmacokinetic Profiles Y-3 for Injection Drug-drug Interaction Repaglinide Tablets Warfarin Sodium Tablets Omeprazole Enteric-coated Capsules Safty

Start date: 2025-05-18
Primary completion: 2025-06-29
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.